Related Experiment Video
Updated: Aug 14, 2026
09:12
Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
Published on: June 14, 2024
FECH, a novel metabolic target influencing CAR T-cell phenotype and function
Marsha Pellegrino1, Simone Vespa2, Illari Salvatori3
1Department of Onco-Hematology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Biomarker Research
|August 13, 2026
Summary
Linsitinib (LIN) enhances chimeric antigen receptor (CAR) T-cell therapy for neuroblastoma by killing tumor cells and improving CAR T-cell function. This involves modulating heme metabolism, suggesting new therapeutic strategies.
Area of Science:
- Immunology
- Oncology
- Cellular Metabolism
Background:
- Chimeric antigen receptor (CAR) T-cell therapy targeting GD2 shows promise for neuroblastoma (NB).
- Incomplete responses necessitate improved CAR T-cell efficacy and persistence.
- Linsitinib (LIN) previously enhanced CAR T-cell therapy in other cancers.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...